EP1001747A1 - Compositions destinees a une administration par voie nasale - Google Patents

Compositions destinees a une administration par voie nasale

Info

Publication number
EP1001747A1
EP1001747A1 EP98940262A EP98940262A EP1001747A1 EP 1001747 A1 EP1001747 A1 EP 1001747A1 EP 98940262 A EP98940262 A EP 98940262A EP 98940262 A EP98940262 A EP 98940262A EP 1001747 A1 EP1001747 A1 EP 1001747A1
Authority
EP
European Patent Office
Prior art keywords
composition according
oil
fatty acid
mono
amphiphilic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98940262A
Other languages
German (de)
English (en)
Inventor
Anthony Guy SmithKline Beecham Pharmac. HATTON
Jane Elizabeth SmithKline Beecham Pharm. HILTON
Hugh SmithKline Beecham Pharmaceuticals SCOTT
Teresita Regina Geradine SmithKline Bee TALLON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9716805.8A external-priority patent/GB9716805D0/en
Priority claimed from GBGB9806682.2A external-priority patent/GB9806682D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1001747A1 publication Critical patent/EP1001747A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • the present invention relates to a novel composition for nasal administration of medicaments.
  • the nasal passages may be used as a route of administration, for instance an ointment such as Bactroban Nasal may be applied to the anterior nares of the nose for a local topical effect.
  • Spray formulations may applied to the nostrils.
  • medicaments may administered to the lungs via the nostrils, using an aerosol or nebuliser.
  • the nasal passages comprise mucosal tissues which might be used as means of systemically delivering a medicament. Such local topical or systemic delivery would be enhanced if the formulation was to have a prolonged residence time in the nasal passages.
  • the present invention provides a sprayable composition adapted for prolonged residence in the nasal passage, in particular the nasal pharynx, which comprises:
  • Amphiphilic agents are substances containing both hydrophilic and lipophilic groups. In liquid form, these agents are generally capable of spontaneous self-association in the presence of water, with a consequent increase in viscosity. This self-association results in a change in properties ranging from the formation of viscous liquids to semi-rigid gels. This behaviour has been characterised as due to the formation of long range order in the liquid system giving several distinct phases which have been called "liquid crystalline phases”.
  • Materials known to exhibit such properties and which are suitable for use in a medicament formulation include mono-glycerides such as mono-olein and mono-linolein, phospholipids such as phosphatidyl cholines, and galactolipids such as galactoyl- diglycerides.
  • the monoglycerides are long-chain fatty acid monoglycerides, optionally comprising up to 10% (w/w) of a long-chain fatty acid diglyceride and/or a small amount by weight of a free long-chain fatty acid.
  • the mono- and di-glycerides may each include blends of different long-chain fatty acid mono- and di-glycerides.
  • Suitable long-chain fatty acid monoglycerides include glycerol monooleate, glycerol monopalmitate and glycerol monostearate.
  • MYVEROL such as MYVEROL 18-99, MYVATEX, MYVAPLEX, and GMORPHIC 80 respectively, from Eastman Kodak Chemicals, Rochester, New York.
  • a further useful long-chain fatty acid monoglyceride- containing product is ARLACEL 186 (available from ICI Americas Inc.) which includes, in addition to glycerol monooleate, propylene glycol (10%).
  • the main fatty acids of MYVEROL 18-99 are oleic acid (61%), linoleic acid (21%), linolenic acid (9%) and palmitic acid (4%).
  • the major fatty acid component is a Ci g-saturated, monounsaturated or polyunsaturated fatty acid, preferably a C i g-monounsaturated or polyunsaturated fatty acid.
  • the monoglyceride will have an HLB value in the range of about 2.5 to 6.
  • the HLB value of the product MYVEROL 18-99 is 3.7.
  • the amphiphilic substance is preferably glyceryl mono-oleate (mono-olein).
  • glyceryl monooleate is a material which is predominantly glyceryl mono-oleate but also contains minor amounts of related mono and di-glycerides. Accordingly, the amount that is effective in a particular spray formulation will vary dependent on the level of glyceryl mono-oleate in the commercial material used.
  • a diluent is selected on the basis of compatibility e.g. producing a stable blend with the amphiphilic agent, and the ability to achieve a sprayable blend without excessive dilution that will reduce the self-association on contact with water and detract from the desired viscosity increase.
  • a diluent is a pharmaceutically acceptable oil, most preferably a fatty acid triglyceride, typically vegetable (i.e. plant derived) oil, since mineral oils such as paraffin oil have been implicated in undesirable side effects when inhaled. Suitable vegetable oils include coconut oil, sesame oil and soya bean oil.
  • the preferred diluent is a vegetable oil, most preferably coconut oil, that has been fractionated so that it is predominantly medium chain length triglycerides.
  • the proportion of amphiphilic agent to oil is from 2:1 to 1 :4, preferably 1 :1 to 1 :2.
  • the amount of diluent is adjusted so that the formulation is of a viscosity that is suitable for spray delivery at 20°C or above.
  • Suitable medium-chain fatty acid triglycerides for use in the present invention may be of natural, semi-synthetic or synthetic origin and may include blends of different medium chain fatty acid triglycerides.
  • the term "medium-chain fatty acid” as used herein refers to a fatty acid having from 6 to 12, preferably 8 to 10 carbon atoms which may be branched or unbranched, preferably unbranched and which may be optionally substituted.
  • Certain neutral plant oils, such as fractionated coconut oils provide convenient sources of medium-chain fatty acid triglycerides.
  • the triglyceride suitably comprises from 50 to 100%> (w/w) of caprylic (Cg) acid and from 0 to 50% (w/w) of capric (Ci Q) acid triglycerides.
  • Suitable examples include those available under the trade names MYRITOL; CAPTEX (Karlshams Lipid Specialties, Columbus OH), for instance CAPTEX 355, CAPTEX 300, CAPTEX 350, CAPTEX 850 and CAPTEX 8000; MIGLYOL (BASF), for instance the grades MIGLYOL 810, MIGLYOL 812 AND MIGLYOL 818 (which also comprises a linoleic acid triglyceride) and MAZOL 1400 (Mazer Chemical, Guernee, II).
  • the fatty acid content of representative products is: CAPTEX 355TM - CAPROIC ACID (2%), CAPRYLIC ACID (55%) and capric acid (42%); CAPTEX 8000 - at least 98% caprylic acid, MYGOL 810 - caproic acid (2%), caprylic acid (65-75%), capric acid (25-35%) and MIGLYOL 812 - caproic acid (3%), caprylic acid (50-65%), capric acid (30-45%) and lauric acid (5%) (manufacturer's data).
  • the sprayable formulations of this invention are especially suitable for nasal delivery, because in the humid environment of the nasal passages they increase in viscosity by contact with water, and so are better able to resist wash-out when in contact with nasal surfaces.
  • the prolonged residence time of formulations of the present invention in the nasal passages, especially the nasal pharynx, makes them particularly suitbable for topical treatment with local action or, since it provides prolonged contact of the formulation with an absorptive region, systemic delivery of a medicament.
  • Suitable medicaments include antibiotics, for instance mupirocin or a pharmaceutically acceptable salt or ester thereof
  • An antibiotic such as mupirocin may be used in the prophylactic treatment of recurrent sinusitis, and otitis media.
  • Suitable pharmaceutically acceptable salts of mupirocin are well known in the art and include alkali metal salts such as sodium and lithium and alkaline earth metal salts such as calcium, of which the calcium salt is preferred, in particular the crystalline dihydrate from thereof described in EP 0 167 856-A (Beecham Group).
  • alkali metal salts such as sodium and lithium
  • alkaline earth metal salts such as calcium
  • Other suitable salts include silver and aluminium salts and ammonium and substituted- ammonium salts.
  • the salts may be anhydrous or may be in the form of pharmaceutically acceptable solvates, for instance alcoholates and, especially, hydrates.
  • Preferred salts include the calcium, silver and lithium salts, in particular the calcium salt.
  • the crystalline salt is preferably used, especially the crystalline hydrated calcium salt, more preferably the crystalline dihydrate salt.
  • esters of mupirocin are well known in the art and include lower alkyl esters, especially the methyl and ethyl esters.
  • the medicament is suspended in a non-aqueous carrier, it is preferably present as a finely divided powder. This may be achieved by milling, and most suitably by micronising (fluid energy milling) so that the medicament has a particle size less than 100 ⁇ m, preferably less than 10 ⁇ m.
  • an antibiotic will be used at between 0.1 and 10%, preferably 2 and 8%, typically about 4-6%, by weight of the formulation. It is preferred to use a relatively high dosage level, to reduce the risk of the development of bacterial resistance. Also, to avoid excessive spray volumes which will be uncomfortable in nasal administration, the medicament is preferably present at a relatively high loading compared to other topical administration formulations.
  • mupirocin may be added at a level of 4% w/w to a carrier based on coconut oil and glycerylmono-oleate, so that a sprayed dose of 125 ⁇ l will deliver approximately 5 mg approximately 5 mg of mupirocin.
  • Formulations of the present invention may be administered by a conventional pump dispenser suitable for nasal administration.
  • a conventional pump dispenser suitable for nasal administration.
  • the formulation is preferably sprayed into the nasal passages where natural processes carry the medicament through the nasal passages to reach deep seated sites of infection.
  • the viscosity increase on contact with moisture prolongs the residence of the medicament and prevents early wash-out.
  • amphiphilic agent and non-aqueous diluent are typically in the preferred forms described above.
  • composition of this invention may be produced by conventional pharmaceutical techniques.
  • amphiphilic substance and diluent may be blended by mixing together at an elevated temperature.
  • the mixture may then be cooled to room temperature, and, after the addition of any further optional ingredients, stirred to ensure adequate dispersion.
  • the medicament may be added during hot preparation of the base, or may be added with additional ingredients after cooling of the base. If necessary, the composition may be provided in sterile condition.
  • Optional ingredients that may be added if desired include colourings and flavourings.
  • the invention is illustrated by the following Example.
  • Example A carrier for a nasal spray formulation was prepared by forming a blend of 67% w/w fractionated coconut oil (medium chain length)* and 33% w/w of glyceryl mono-oleate **. To this blend was added 0.2% w/w of powdered lemon juice flavour, followed by 4% w/w of micronized calcium Mupirocin.
  • the resultant formulation has a viscosity which is sprayable at 20°C or above.
  • the liquid When sprayed into the nose of a patient, the liquid coats the nasal passages and contact with moisture inside the nose (from the mucous membranes, and the humid environment generally) causes the carrier to thicken. This prolongs the residence time of the sprayed formulation on the nasal surfaces.
  • a spray volume of about 125 ⁇ l contains approximately 5 mg Mupirocin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles compositions adaptées pour une administration de médicaments par voie nasale.
EP98940262A 1997-08-09 1998-08-05 Compositions destinees a une administration par voie nasale Withdrawn EP1001747A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9716805 1997-08-09
GBGB9716805.8A GB9716805D0 (en) 1997-08-09 1997-08-09 Novel composition and use
GBGB9806682.2A GB9806682D0 (en) 1998-03-27 1998-03-27 Novel composition
GB9806682 1998-03-27
PCT/EP1998/004972 WO1999007341A1 (fr) 1997-08-09 1998-08-05 Compositions destinees a une administration par voie nasale

Publications (1)

Publication Number Publication Date
EP1001747A1 true EP1001747A1 (fr) 2000-05-24

Family

ID=26312034

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98940262A Withdrawn EP1001747A1 (fr) 1997-08-09 1998-08-05 Compositions destinees a une administration par voie nasale

Country Status (4)

Country Link
EP (1) EP1001747A1 (fr)
JP (1) JP2001513493A (fr)
CA (1) CA2299298A1 (fr)
WO (1) WO1999007341A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057907A1 (en) * 2002-09-23 2004-03-25 Leonard Mackles Dri-nasal sprays
US8211448B2 (en) 2003-07-07 2012-07-03 Nares Ab Microemulsions and its use for preventing airway diseases
PL1648412T3 (pl) * 2003-07-07 2008-04-30 Nares Ab Mikroemulsje i ich zastosowanie do zapobiegania chorobom dróg oddechowych
DE102011010668A1 (de) * 2011-02-08 2012-08-09 Ursapharm Arzneimittel Gmbh Wässrige pharmazeutische Zusammensetzung zur Prävention und/oder Therapie allergisch gereizter Nasenschleimhaut und dessen Verwendung
US20120219644A1 (en) * 2011-02-28 2012-08-30 Harrington Carolyn J Coconut oil-based intranasal composition and use
US20170189539A1 (en) * 2014-05-13 2017-07-06 Paragon Nordic Ab Composition having improved spraying characteristics comprising vegetable oils and triglycerides and/or mineral oils

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE59628B1 (en) * 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
WO1997013528A1 (fr) * 1995-10-12 1997-04-17 Gs Development Ab Composition pharmaceutique pour l'administration d'un principe actif sur ou au travers d'une surface cutanee ou muqueuse
CA2267248A1 (fr) * 1996-10-01 1998-04-09 Smithkline Beecham P.L.C. Utilisation de la mupirocine dans la fabrication d'un medicament destine au traitement d'infections bacteriennes associees a la colonisation du rhino-pharynx par des organismes pathogenes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9907341A1 *

Also Published As

Publication number Publication date
CA2299298A1 (fr) 1999-02-18
JP2001513493A (ja) 2001-09-04
WO1999007341A1 (fr) 1999-02-18

Similar Documents

Publication Publication Date Title
AU724070B2 (en) Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
US6426363B1 (en) Calcium mupirocin sprayable formulation
JP5192473B2 (ja) ポリグリコリシスされたグリセリドを含有するエアゾール薬処方物
JPH0811725B2 (ja) 薬剤を含むクロロフルオロカ−ボンエアゾ−ル噴射剤配合物
AU594264B2 (en) Therapeutic agents
JP2001503404A (ja) 局所的塗布具のためのアシクロビルを含む抗ヘルペス薬学的組成物
EP1189597A1 (fr) Compositions a noyau huileux destinees a la liberation prolongee de medicaments hydrophobes
KR20040009017A (ko) 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
WO2000001390A1 (fr) Formulations topiques d'aciclovir
EP1001747A1 (fr) Compositions destinees a une administration par voie nasale
CA1249223A (fr) Formulations de medicaments solides et suspensions stables
FI101600B (fi) Menetelmä farmaseuttisen formulaation valmistamiseksi
WO1999012520A1 (fr) Compositions adaptees pour un sejour prolonge dans le rhino-pharynx
ES2272508T3 (es) Formulacion liposomica de propionato de clobetasol.
US5275821A (en) Amantadine hydrochloride suspension with enhanced dissolution characteristics for use in soft gelatin capsules
JP3277735B2 (ja) ナフトエ酸誘導体の吸収促進組成物
PT1156829E (pt) ''formulação estável contendo fumagilina''
JPH01226817A (ja) ４‐アロイルイミダゾール‐２‐オン類に対する製薬組成物
TW202228668A (zh) 外用醫藥組成物
JPH09263538A (ja) アセチルサリチル酸とトコフェロールに基づく安定な製薬組成物
US20170319641A1 (en) Mucoadhesive emollient
JPH11279024A (ja) 皮膚外用剤
JPH06211652A (ja) カルボシステインを含有するカプセル製剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 20021022

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030305